BARDA DRIVe EZ-BAA (EZBAA - 22-100-SOL-00003)

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

BARDA - ASPR / DAAPPO / BARDA DCMA

Contract Value

Not provided

Codes & Classification
Solicitation Number

DRIVeEZBAA22100SOL00003

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Classification Code

AN13

Additional Details
Set Aside

None

Place of Performance

-

SourceSAM
The Biomedical Advanced Research and Development Authority (BARDA), operating under the Office of the Assistant Secretary for Preparedness and Response (ASPR), has issued the reconstituted Easy Broad Agency Announcement (EZ-BAA), procurement identifier DRIVeEZBAA22100SOL00003. This active solicitation supersedes previous versions and is designed to support innovative research and development activities in biotechnology, specifically excluding nanobiotechnology, as classified under NAICS Code 541714 and Product Service Code AN13. Purpose and Scope: The BARDA DRIVe EZ-BAA aims to accelerate the development and deployment of transformative medical countermeasures and technologies that address pressing public health threats. Through this mechanism, BARDA seeks to engage a broad spectrum of partners in advancing solutions across multiple Areas of Interest (AOIs), which are periodically updated, opened, paused, or closed via formal amendments. The scope encompasses early-stage research, advanced development, and potential commercialization of products and platforms that can enhance national health security and emergency preparedness. Key Requirements and Objectives: Respondents are invited to propose projects aligned with the specific AOIs outlined in the solicitation and its amendments. These AOIs cover a diverse range of topics, including but not limited to: - ReDIRECT (AOI #15) - Lab at Home (AOI #16) - Digital Medical Countermeasures (MCMs) (AOI #17) - Host-Directed Therapeutics (AOI #18) - Healing Lungs (AOI #19) - DRIVe Forward (AOI #20) - Vaccines on Demand (AOI #21) - ReBooT (AOI #22) - Host-Based Diagnostics (AOI #23) - REPAIR (AOI #24) - FASTx (AOI #25) - Agnostic Diagnostic (AOI #26) - Stopping Secondary Spread (AOI #27) - Influenza Vaccine Innovation (AOI #28) - Type to Treat (AOI #29) Each AOI is subject to its own set of requirements, closing dates, and revision history, as detailed in the corresponding amendments. Contractors should carefully review the latest amendment documents to ensure alignment with current priorities and eligibility criteria. The expected deliverables typically include research findings, prototype development, validation studies, and other outputs that contribute to the advancement of medical countermeasures and related technologies. Contracting Entity and Contact Information: The contracting entity for this opportunity is BARDA - ASPR / DAAPPO / BARDA DCMA, a federal office dedicated to supporting advanced research and development in health security. The primary point of contact for inquiries and submissions is the BARDA DCMA DRIVe Team, reachable via email at [email protected]. Location and Classification: This solicitation is issued at the federal level and is classified under NAICS Code 541714 (Research and Development in Biotechnology, except Nanobiotechnology), with the 2022 version year. The Product Service Code is AN13, further specifying the focus on biotechnology R&D. Procurement Type and Special Considerations: The EZ-BAA is a Broad Agency Announcement, which allows for flexible, merit-based selection of proposals that address the stated research interests. The solicitation is not restricted to a particular set-aside category, making it accessible to a wide range of entities, including small businesses, academic institutions, and other eligible organizations. Contractors should note that AOIs are subject to change throughout the lifecycle of the announcement, with new topics added and others paused or closed as BARDA’s strategic priorities evolve. The removal of the Rough Order of Magnitude (ROM) requirement in recent amendments may impact proposal preparation. Constant Elements: Throughout the contract lifecycle, the following elements remain consistent: - The overarching goal of advancing biotechnology solutions for public health preparedness. - The federal contracting entity (BARDA - ASPR / DAAPPO / BARDA DCMA). - The use of the EZ-BAA mechanism to solicit and evaluate proposals. - The classification under NAICS 541714 and PSC AN13. - The primary contact information and submission process via the DRIVe Team. Contractors interested in this opportunity should regularly monitor the solicitation page on SAM.gov (https://sam.gov/opp/42afa51fe02949309a6bdd4ce111f1c4/view) and review all amendments to stay informed of the latest AOI openings, closings, and revisions. The response deadline is set for October 18, 2027, providing an extended window for proposal development and submission. In summary, the BARDA DRIVe EZ-BAA represents a dynamic and ongoing opportunity for organizations engaged in biotechnology R&D to contribute to the nation’s health security through innovative research and product development. Careful attention to the evolving Areas of Interest and amendment details is essential for successful participation.
Documents38